Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Doc Bones who wrote (1260)	6/26/2000 2:27:00 AM
From: Mike McFarland	Respond to of 52153

Somebody already pointed out that biotech share prices were already suffering profit-taking by the time Clinton and Blair did their thing. There was strong momentum up, and shares fell just as fast or faster than they had risen. Clinton/Blair certainly added to the panic however--the timing was perfect for accellerating the decline. Buying and then selling last week: finance.yahoo.com Just look at those marketcaps! I'd sure like to see some of these rich genomics companies go shoppin for some of the cheap, neglected second and third tier biotechs out there--that could really help out my portfolio! I think you cannot own the highfliers now--where are they going to be five years from now? Maybe down 50% on a few of them. I'd trade Celera and HGSI for those neglected third tier stocks I mentioned, say a GZMO or an AXPH, which both have angles on genomics and such. (heh, shameless). Of course 'angle on genomics', that comment is a bit lame--what biotech company doesn't do genomics? Well, Genzyme Molecular has that SAGE tool, and their CEO recently claimed their antigen discovery was "second to none". Axys called themselves a gene-to-grug company a lot, still waiting.